Literature DB >> 31665686

Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes?

Ali Shoeibi1, Irene Litvan2, Jorge L Juncos3, Yvette Bordelon4, David Riley5, David Standaert6, Stephen G Reich7, David Shprecher8, Deborah Hall9, Connie Marras10, Benzi Kluger11, Nahid Olfati1, Joseph Jankovic12.   

Abstract

The International Parkinson Disease and Movement Disorder Society PSP study group (IPMDS-PSP) recently published new clinical diagnostic criteria for progressive supranuclear palsy (PSP). Currently, there is no data regarding the accuracy of these sets of criteria for differentiating various PSP phenotypes. We discuss the accuracy of the IPMDS-PSP criteria for differentiation of patients with the PSP- Richardson phenotype (PSP-RS) from those with the PSP-Parkinsonism (PSP-P) using data from a sample of 274 clinically diagnosed PSP patients participating in the Environmental Genetic PSP (ENGENE-PSP) case control study. Using National Institute of Neurological Disorders and Stroke and the Society for PSP (NINDS-SPSP) criteria and the Williams criteria we categorized 259 of these patients as probable PSP-RS and 15 as PSP-P. The IPD-MDS PSP-RS and PSP-P criteria were unable to distinguish the PSP-RS from the PSP-P phenotypes in this sample. Nearly all (92.6%; 240 out of 259) the PSP-RS patients and over half (60%; 9 out of 15) of the PSP-P patients fulfilled both the IPMDS criteria for PSP-RS and PSP-P. Applying the newly proposed multiple allocation extinction rules decreased the number of overlapping diagnoses among the NINDS-SPSP PSP-RS patients, however problems remained in the PSP-P group. Diagnostic accuracy might be improved by modification of timelines for development of falls and other parkinsonian features.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Criteria; Diagnosis; Progressive supranuclear palsy

Mesh:

Year:  2019        PMID: 31665686      PMCID: PMC6914266          DOI: 10.1016/j.parkreldis.2019.10.012

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  21 in total

1.  Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases.

Authors:  Sam Birdi; Ali H Rajput; Mark Fenton; Jeffery R Donat; Bohdan Rozdilsky; Christopher Robinson; Rob Macaulay; David George
Journal:  Mov Disord       Date:  2002-11       Impact factor: 10.338

2.  Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders.

Authors:  Irene Litvan; Kailash P Bhatia; David J Burn; Christopher G Goetz; Anthony E Lang; Ian McKeith; Niall Quinn; Kapil D Sethi; Cliff Shults; Gregor K Wenning
Journal:  Mov Disord       Date:  2003-05       Impact factor: 10.338

Review 3.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop.

Authors:  I Litvan; Y Agid; D Calne; G Campbell; B Dubois; R C Duvoisin; C G Goetz; L I Golbe; J Grafman; J H Growdon; M Hallett; J Jankovic; N P Quinn; E Tolosa; D S Zee
Journal:  Neurology       Date:  1996-07       Impact factor: 9.910

4.  Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study.

Authors:  Irene Litvan; Peter S J Lees; Christopher R Cunningham; Shesh N Rai; Alexander C Cambon; David G Standaert; Connie Marras; Jorge Juncos; David Riley; Stephen Reich; Deborah Hall; Benzi Kluger; Yvette Bordelon; David R Shprecher
Journal:  Mov Disord       Date:  2016-02-08       Impact factor: 10.338

5.  Progression of two Progressive Supranuclear Palsy phenotypes with comparable initial disability.

Authors:  Ali Shoeibi; Irene Litvan; Eduardo Tolosa; Teodoro Del Ser; Euyhyun Lee
Journal:  Parkinsonism Relat Disord       Date:  2019-07-09       Impact factor: 4.891

6.  Clinical outcomes of progressive supranuclear palsy and multiple system atrophy.

Authors:  S S O'Sullivan; L A Massey; D R Williams; L Silveira-Moriyama; P A Kempster; J L Holton; T Revesz; A J Lees
Journal:  Brain       Date:  2008-04-02       Impact factor: 13.501

7.  Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.

Authors:  I Litvan; C A Mangone; A McKee; M Verny; A Parsa; K Jellinger; L D'Olhaberriague; K R Chaudhuri; R K Pearce
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

Review 8.  The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy): a reappraisal.

Authors:  S E Daniel; V M de Bruin; A J Lees
Journal:  Brain       Date:  1995-06       Impact factor: 13.501

9.  Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism.

Authors:  David R Williams; Rohan de Silva; Dominic C Paviour; Alan Pittman; Hilary C Watt; Linda Kilford; Janice L Holton; Tamas Revesz; Andrew J Lees
Journal:  Brain       Date:  2005-03-23       Impact factor: 13.501

10.  Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.

Authors:  Günter U Höglinger; Gesine Respondek; Maria Stamelou; Carolin Kurz; Keith A Josephs; Anthony E Lang; Brit Mollenhauer; Ulrich Müller; Christer Nilsson; Jennifer L Whitwell; Thomas Arzberger; Elisabet Englund; Ellen Gelpi; Armin Giese; David J Irwin; Wassilios G Meissner; Alexander Pantelyat; Alex Rajput; John C van Swieten; Claire Troakes; Angelo Antonini; Kailash P Bhatia; Yvette Bordelon; Yaroslau Compta; Jean-Christophe Corvol; Carlo Colosimo; Dennis W Dickson; Richard Dodel; Leslie Ferguson; Murray Grossman; Jan Kassubek; Florian Krismer; Johannes Levin; Stefan Lorenzl; Huw R Morris; Peter Nestor; Wolfgang H Oertel; Werner Poewe; Gil Rabinovici; James B Rowe; Gerard D Schellenberg; Klaus Seppi; Thilo van Eimeren; Gregor K Wenning; Adam L Boxer; Lawrence I Golbe; Irene Litvan
Journal:  Mov Disord       Date:  2017-05-03       Impact factor: 10.338

View more
  6 in total

1.  Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.

Authors:  Tien Dam; Adam L Boxer; Lawrence I Golbe; Günter U Höglinger; Huw R Morris; Irene Litvan; Anthony E Lang; Jean-Christophe Corvol; Ikuko Aiba; Michael Grundman; Lili Yang; Beth Tidemann-Miller; Joseph Kupferman; Kristine Harper; Kubra Kamisoglu; Michael J Wald; Danielle L Graham; Liz Gedney; John O'Gorman; Samantha Budd Haeberlein
Journal:  Nat Med       Date:  2021-08-12       Impact factor: 87.241

2.  The Burden of Progressive Supranuclear Palsy on Patients, Caregivers, and Healthcare Systems by PSP Phenotype: A Cross-Sectional Study.

Authors:  Demetris Pillas; Alexander Klein; Teresa Gasalla; Andreja Avbersek; Alexander Thompson; Jack Wright; Jennifer Mellor; Anna Scowcroft
Journal:  Front Neurol       Date:  2022-07-04       Impact factor: 4.086

3.  High-quality nursing intervention can improve negative emotions, quality of life and activity of daily living of elderly patients with Parkinson's disease.

Authors:  Yihui Gui; Youya Zhou
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

4.  Is the Phenotype Designation by PSP-MDS Criteria Stable Throughout the Disease Course and Consistent With Tau Distribution?

Authors:  Javier Sánchez-Ruiz de Gordoa; Victoria Zelaya; Paula Tellechea-Aramburo; Blanca Acha; Miren Roldán; Carlos López-Molina; Valle Coca; Arkaitz Galbete; Maite Mendioroz; M Elena Erro
Journal:  Front Neurol       Date:  2022-02-03       Impact factor: 4.003

Review 5.  Clinical Spectrum of Tauopathies.

Authors:  Nahid Olfati; Ali Shoeibi; Irene Litvan
Journal:  Front Neurol       Date:  2022-07-14       Impact factor: 4.086

6.  Of Criteria and Men-Diagnosing Atypical Parkinsonism: Towards an Algorithmic Approach.

Authors:  Liviu Cozma; Mioara Avasilichioaei; Natalia Dima; Bogdan Ovidiu Popescu
Journal:  Brain Sci       Date:  2021-05-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.